Evidence map›Paper›PMID 35552752›Full record

ArticleThe oncologist2022

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation.

Richard S P Huang, Julie Y Tse, Lukas Harries, Ryon P Graf, Douglas I Lin, Karthikeyan Murugesan, Matthew C Hiemenz, Vamsi Parimi, Tyler Janovitz, Brennan Decker and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Richard S P HuangFoundation Medicine, Inc., Cambridge, MA, USA.ORCID 0000-0001-8395-5168
Julie Y TseFoundation Medicine, Inc., Cambridge, MA, USA.
Lukas HarriesFoundation Medicine, Inc., Cambridge, MA, USA.
Ryon P GrafFoundation Medicine, Inc., Cambridge, MA, USA.
Douglas I LinFoundation Medicine, Inc., Cambridge, MA, USA.
Karthikeyan MurugesanFoundation Medicine, Inc., Cambridge, MA, USA.
Matthew C HiemenzFoundation Medicine, Inc., Cambridge, MA, USA.
Vamsi ParimiFoundation Medicine, Inc., Cambridge, MA, USA.
Tyler JanovitzFoundation Medicine, Inc., Cambridge, MA, USA.
Brennan DeckerFoundation Medicine, Inc., Cambridge, MA, USA.
Eric SeversonFoundation Medicine, Inc., Cambridge, MA, USA.
Mia A LevyFoundation Medicine, Inc., Cambridge, MA, USA.
Shakti H RamkissoonFoundation Medicine, Inc., Cambridge, MA, USA.
Julia A ElvinFoundation Medicine, Inc., Cambridge, MA, USA.
Jeffrey S RossFoundation Medicine, Inc., Cambridge, MA, USA.
Erik A WilliamsFoundation Medicine, Inc., Cambridge, MA, USA.
Foundation Medicine (United States)Rush University Medical Center · USSUNY Upstate Medical University · USUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the current study, we examined the real-world prevalence of highly pigmented advanced melanomas (HPMel) and the clinicopathologic, genomic, and ICPI biomarker signatures of this class of tumors. MATERIALS AND

methodsOur case archive of clinical melanoma samples for which the ordering physician requested testing for both PD-L1 immunohistochemistry (IHC) and comprehensive genomic profiling (CGP) was screened for HPMel cases, as well as for non-pigmented or lightly pigmented advanced melanoma cases (LPMel).

resultsOf the 1268 consecutive melanoma biopsies in our archive that had been submitted for PD-L1 IHC, 13.0% (165/1268) were HPMel and 87.0% (1103/1268) were LPMel. In the HPMel cohort, we saw a significantly lower tumor mutational burden (TMB, median 8.8 mutations/Mb) than in the LPMel group (11.4 mut/Mb), although there was substantial overlap. In examining characteristic secondary genomic alterations (GA), we found that the frequencies of GA in TERTp, CDKN2A, TP53, and PTEN were significantly lower in the HPMel cases than in LPMel. A higher rate of GA in CTNNB1, APC, PRKAR1A, and KIT was identified in the HPMel cohort compared with LPMel.

conclusionsIn this study, we quantified the failure rates of melanoma samples for PD-L1 testing due to high melanin pigmentation and showed that CGP can be used in these patients to identify biomarkers that can guide treatment decisions for HPMel patients. Using this practical clinical definition for tumor pigmentation, our results indicate that HPMel are frequent at 13% of melanoma samples, and in general appear molecularly less developed, with a lower TMB and less frequent secondary GA of melanoma progression.

Indexed as

B7-H1 AntigenMelanomaBiomarkers, TumorGenomicsHumansMutationPigmentationB7-H1 AntigenBiomarkers, Tumorbiomarkerscomprehensive genomic profilingheavily pigmentedmelanomasPD-L1 immunohistochemistry

Identifiers

PMID35552752
PMCPMC9355815
OpenAlexW4225763425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.